348 related articles for article (PubMed ID: 17124785)
1. Sublingual vaccines based on wild-type recombinant allergens.
Van Overtvelt L; Razafindratsita A; St-Lu N; Didierlaurent A; Batard T; Lombardi V; Martin E; Moingeon P
Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):247-9. PubMed ID: 17124785
[TBL] [Abstract][Full Text] [Related]
2. Immune mechanisms of allergen-specific sublingual immunotherapy.
Moingeon P; Batard T; Fadel R; Frati F; Sieber J; Van Overtvelt L
Allergy; 2006 Feb; 61(2):151-65. PubMed ID: 16409190
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy: from biological extracts to recombinant allergens.
Moingeon P
Allergy; 2006; 61 Suppl 81():15-9. PubMed ID: 16792601
[TBL] [Abstract][Full Text] [Related]
4. Adjuvants and vector systems for allergy vaccines.
Moingeon P; Lombardi V; Saint-Lu N; Tourdot S; Bodo V; Mascarell L
Immunol Allergy Clin North Am; 2011 May; 31(2):407-19, xii. PubMed ID: 21530828
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
[TBL] [Abstract][Full Text] [Related]
6. Immunological mechanisms of sublingual allergen-specific immunotherapy.
Novak N; Bieber T; Allam JP
Allergy; 2011 Jun; 66(6):733-9. PubMed ID: 21251016
[TBL] [Abstract][Full Text] [Related]
7. Bifidobacterium bifidum NCC 453 promotes tolerance induction in murine models of sublingual immunotherapy.
Moussu H; Van Overtvelt L; Horiot S; Tourdot S; Airouche S; Zuercher A; Holvoet S; Prioult G; Nutten S; Mercenier A; Mascarell L; Moingeon P
Int Arch Allergy Immunol; 2012; 158(1):35-42. PubMed ID: 22205338
[TBL] [Abstract][Full Text] [Related]
8. The future of sublingual immunotherapy.
Marcucci F; Duse M; Frati F; Incorvaia C; Marseglia GL; La Rosa M
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):31-3. PubMed ID: 19944008
[TBL] [Abstract][Full Text] [Related]
9. Immunological mechanisms of sublingual immunotherapy.
Akdis CA; Barlan IB; Bahceciler N; Akdis M
Allergy; 2006; 61 Suppl 81():11-4. PubMed ID: 16792600
[TBL] [Abstract][Full Text] [Related]
10. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction.
Saint-Lu N; Tourdot S; Razafindratsita A; Mascarell L; Berjont N; Chabre H; Louise A; Van Overtvelt L; Moingeon P
Allergy; 2009 Jul; 64(7):1003-13. PubMed ID: 19220212
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with peptides.
Moldaver D; Larché M
Allergy; 2011 Jun; 66(6):784-91. PubMed ID: 21507007
[TBL] [Abstract][Full Text] [Related]
12. Update on sublingual immunotherapy treatment regimes.
Spangfort MD
Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):244. PubMed ID: 17124783
[No Abstract] [Full Text] [Related]
13. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation.
Razafindratsita A; Saint-Lu N; Mascarell L; Berjont N; Bardon T; Betbeder D; Van Overtvelt L; Moingeon P
J Allergy Clin Immunol; 2007 Aug; 120(2):278-85. PubMed ID: 17531296
[TBL] [Abstract][Full Text] [Related]
14. Allergen-related approaches to immunotherapy.
Rolland JM; Gardner LM; O'Hehir RE
Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
[TBL] [Abstract][Full Text] [Related]
15. The history of sublingual immunotherapy.
Pajno GB; Barberi S
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):1-3. PubMed ID: 19944001
[TBL] [Abstract][Full Text] [Related]
16. Local immunological mechanisms of sublingual immunotherapy.
Allam JP; Novak N
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):571-8. PubMed ID: 22001742
[TBL] [Abstract][Full Text] [Related]
17. Intralymphatic immunotherapy: from the rationale to human applications.
Senti G; Johansen P; Kündig TM
Curr Top Microbiol Immunol; 2011; 352():71-84. PubMed ID: 21725898
[TBL] [Abstract][Full Text] [Related]
18. [The mechanisms of allergen-specific immunotherapy more clear].
Rak S
Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1935-7. PubMed ID: 18681375
[No Abstract] [Full Text] [Related]
19. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?
Allam JP; Stojanovski G; Friedrichs N; Peng W; Bieber T; Wenzel J; Novak N
Allergy; 2008 Jun; 63(6):720-7. PubMed ID: 18445186
[TBL] [Abstract][Full Text] [Related]
20. Lactic acid bacteria as adjuvants for sublingual allergy vaccines.
Van Overtvelt L; Moussu H; Horiot S; Samson S; Lombardi V; Mascarell L; van de Moer A; Bourdet-Sicard R; Moingeon P
Vaccine; 2010 Apr; 28(17):2986-92. PubMed ID: 20175969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
